Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 bird flu vaccine candidate, mRNA-1018. See our latest analysis for Moderna.

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable therapies. The heavily back-loaded deal will see Moderna hand over just $3 ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective. The ...

Shares of Moderna, Inc. (NASDAQ: MRNA) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. What To Know: ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing self-sufficiency and efficiency in drug production. The expansion will create ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Moderna Inc. shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its Covid business.

Moderna Inc (NASDAQ:MRNA) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news. What To Know: The decline continues despite Moderna’s ...

CAMBRIDGE, Mass. — Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12-64 with at ...

Pharma stocks took a fresh hit on Friday following a report in The Washington Post that the U.S. Food and Drug Administration reportedly plans to link COVID-19 vaccines with the deaths of 25 minors.

In the age of artificial intelligence and organizational reinvention, Moderna is taking a big leap by reshaping the traditional corporate structure. The biotech giant recently merged its human ...

Moderna's post-pandemic vaccine demand is weak, with mRESVIA unlikely to gain significant RSV market share due to commoditization and entrenched competitors. Financials remain strained: high costs, ...